Get started
Author

Frederick Briccetti

Observed names: Fred Briccetti, Frederick M. Briccetti
ORCID: 0000-0002-8488-2383
Observed ORCID: 0000-0002-8488-2383
OpenAlex ID: A5034484462
Analysis of CD36 Binding Domains: Ligand Specificity Controlled by Dephosphorylation of an Ectodomain
1993 · Adam S. Asch, Isaac Liu, et al. · Science · 220
Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer
2023 · Deborah Schrag, Hajime Uno, et al. · JAMA · 146
PDF
Thalidomide and rituximab in Waldenstrom macroglobulinemia
2008 · Steven P. Treon, Jacob D. Soumerai, et al. · Blood · 142
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
2021 · Sara M. Tolaney, Nabihah Tayob, et al. · Journal of Clinical Oncology · 138
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
2021 · Kathryn J. Ruddy, Yue Zheng, et al. · Breast Cancer Research and Treatment · 38
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
2024 · Wendy Y. Chen, Karla V. Ballman, et al. · JAMA · 32
Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
2020 · Sara M Tolaney, Lorenzo Trippa, et al. · Cancer Research · 26
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer
2021 · Romualdo Barroso-Sousa, Ines Vaz-Luis, et al. · The Oncologist · 24
PDF
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
2022 · Romualdo Barroso-Sousa, Paolo Tarantino, et al. · npj Breast Cancer · 17
PDF
A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial
2022 · Wendy Y. Chen, Karla V. Ballman, et al. · Journal of Clinical Oncology · 15
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study
2020 · Ines Vaz-Luis, Romualdo Barroso-Sousa, et al. · Journal of Clinical Oncology · 9
Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial)
2020 · Kathryn J. Ruddy, Lorenzo Trippa, et al. · Cancer Research · 9
Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033)
2020 · Ann Partridge, Yue Zheng, et al. · Cancer Research · 5
Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
2022 · Ana C Garrido-Castro, Noah Graham, et al. · Cancer Research · 3
Follicular lymphoma with bilateral testicular and epididymal involvement: Case report and review of the literature
2005 · Eric Jacobsen, Lesley Lomo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3
Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.
2019 · Romualdo Barroso-Sousa, Ines Maria Vaz Duarte Luis, et al. · Journal of Clinical Oncology
Disseminating team training across an academic cancer center and community-based satellites.
2013 · Anne Gross, Susan Mann, et al. · Journal of Clinical Oncology
Works count: 17
Citation count: 827
H-index: 10
I10-index: 10
Year
Topic
Type